Possible applications & planning
The potential applications for our invention are broad, because there are many health conditions where weight gain can lead to health benefits.
To prove that our invention works in patients we strive to conduct Phase 2a studies in the following indications:
Post-operative ileus (POI) occurs in up to 50% of patients who undergo major abdominal surgery (Kuruba et al., 2018). POI is characterized by the inability to tolerate a solid diet, delayed passage of flatus and formed stool, pain and abdominal distension, nausea, vomiting, and accumulation of gas or fluids in the bowel. The causes of POI are multi factorial and include surgical manipulation, inflammatory response, inhibitory neural reflexes, and the secretion of endogenous opioids within the gastrointestinal tract.
Every year approximately 10 million patients undergo major abdominal surgery in the US and EU.
We indicate a peak sales in the order of EUR 200–400M per year for POI.
Orexa has started this Phase 2a study in November 2022.
Anorexia is a complex indication, with the main characteristic that patients refuse to eat. During therapy patients are coached to eat sufficient amounts. It is primarily a psychological problem but also pain and early satiety play a role. These patients could benefit from our drug, because it is expected that the food intake will be promoted. The question is however whether the patients will accept pharmacological treatment (to increase food intake).
The goal of this descriptive study is to answer the question whether there are Anorexia patients who accept benefit from the treatment with our drug.
This Phase 2a study is in preparation and could start relatively soon.
Cachexia & Sarcopenia:
Cachexia is the loss of weight and muscle strength as a consequence of underlying disease (like cancer or COPD).
Sarcopenia is the loss of weight and muscle strength purely as a consequence of ageing. It is caused by changes in food intake and activity.
These are huge markets and we indicate a peak sales of > EUR 1 billion per year for Cachexia & Sarcopenia, if we can prove sufficient health benefits.